Learn Biotech Investing
A structured path through biotech investing — from how the FDA approves drugs to reading clinical readouts, financials, and catalysts. Each topic links evidence-based guides and reports; Spotter can explain unfamiliar terms in the context of the company or event you are researching.
FDA & Regulatory
How the FDA reviews and approves drugs — PDUFA dates, Advisory Committees, Complete Response Letters, and the expedited pathways (Breakthrough, Fast Track, Accelerated, Priority Review) that shape biotech catalysts.
Q3 2026 Biotech Catalyst Calendar: PDUFA Dates and Readouts to Watch
The confirmed PDUFA dates and clinical readouts driving biotech stocks through the rest of Q3 2026 — five FDA decisions and a slate of Phase 2/3 topline data, each traceable to the trial record.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
FDA Refuse to File (RTF): The Rejection Before the Review
A Refuse to File is the FDA declining to even review an application. Learn what triggers an RTF, how it differs from a Complete Response Letter, and what it signals.
What Is a PDUFA Date Extension? Why the FDA Pushes Back Decisions
PDUFA extensions delay an FDA decision by up to three months. Learn why they happen, whether they're bullish or bearish, and how to interpret them as an investor.
What Is FDA Rolling Review? How It Compresses Drug Timelines
Rolling review lets sponsors submit application sections as they're completed instead of all at once. Here's how it works, who qualifies, and what it means for catalyst timing.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
FDA Priority Review: Timing vs. Approval Probability
Check the correct FDA review clock, separate a PDUFA action goal from approval odds, and audit the timing and probability assumptions in a biotech valuation.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
FDA Complete Response Letters: How to Verify a Resubmission Timeline
Separate CRL remediation from the FDA review clock. Check the original letter, resubmission receipt, Class 1 or Class 2 designation, and confirmed goal date.
What Is PDUFA? A Complete Guide for Biotech Investors
Understand PDUFA dates, how the FDA review process works, and why PDUFA action dates are the most important catalysts in biotech investing.
How to Read FDA Advisory Committee (AdCom) Meeting Results
Learn how FDA Advisory Committee meetings work, how to interpret voting results, and what AdCom outcomes mean for biotech stock prices.
Clinical Trials & Data Readouts
How drugs move through Phase 1–3 testing, what endpoints and topline data mean, and how to read a clinical trial like an analyst.
Q3 2026 Biotech Catalyst Calendar: PDUFA Dates and Readouts to Watch
The confirmed PDUFA dates and clinical readouts driving biotech stocks through the rest of Q3 2026 — five FDA decisions and a slate of Phase 2/3 topline data, each traceable to the trial record.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
Surrogate Endpoints in Oncology: ORR, PFS, and Overall Survival
How oncology surrogate endpoints like ORR and PFS relate to overall survival, why they enable faster approvals, and the risks investors must weigh when survival data lag.
Understanding Mechanism of Action (MoA) in Biotech Investing
Why a drug's mechanism of action drives differentiation, competitive risk, and side effects, and how investors can use MoA to evaluate a pipeline without a science degree.
Bispecific Antibodies Explained: Two Targets, One Molecule
How bispecific antibodies engage two targets at once, why T-cell engagers are reshaping oncology, and what investors should weigh versus ADCs and CAR-T.
FDA Refuse to File (RTF): The Rejection Before the Review
A Refuse to File is the FDA declining to even review an application. Learn what triggers an RTF, how it differs from a Complete Response Letter, and what it signals.
ClinicalTrials.gov Trial Start Dates: Recruiting vs Actual Enrollment
Check whether a biotech trial has actually started: distinguish estimated dates, recruiting status, enrollment targets and primary completion, with dated NVG-291 and NAI examples.
Clinical Trial Enrollment: Does the Actual Count Support the Design?
Check estimated versus actual enrollment, the protocol's sample-size assumptions, analysis populations, and follow-up before treating a trial as ready to read out.
mRNA Platforms Beyond Vaccines: The Investment Thesis
How mRNA technology works, why it's a platform rather than a single product, and the opportunities and challenges as developers push beyond vaccines into therapeutics.
What Is FDA Rolling Review? How It Compresses Drug Timelines
Rolling review lets sponsors submit application sections as they're completed instead of all at once. Here's how it works, who qualifies, and what it means for catalyst timing.
AAV Gene Therapy Trials: Eligibility, Dose and Durability
Compare AAV gene therapy evidence using patient eligibility, dose units, endpoints and observed follow-up. Build a trial worksheet before making valuation assumptions.
Open-Label vs Double-Blind Trials: An Investor's Evidence Checklist
Assess an open-label readout using its comparator, randomization, masked outcome assessment and missing data. See which safeguards support a comparison and what remains unknown.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
CAR-T Cell Therapy Explained for Investors
How CAR-T re-engineers a patient's immune cells to fight cancer, the manufacturing and safety challenges that shape its economics, and what investors should watch.
Statistical Significance and P-Values in Clinical Trials
What a p-value actually means, why p<0.05 is the bar, the difference between statistical and clinical significance, and how to avoid being fooled by a 'trend.'
Primary vs Secondary Endpoints: Audit a Trial Readout
Check a clinical trial readout against its endpoint definitions, testing hierarchy and analysis population. Separate confirmatory results from exploratory signals.
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
What Is an Antibody-Drug Conjugate (ADC)? An Investor's Primer
How antibody-drug conjugates deliver potent payloads to cancer cells, the three components that define them, and why ADCs have become one of oncology's hottest modalities.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Patent Expiry in Biotech: How Loss of Exclusivity Impacts Stock Valuations
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Biotech Finance & SEC Filings
Reading the numbers behind a biotech — cash runway, burn rate, dilution, valuation, and the SEC filings (10-K, 10-Q, 8-K, S-1, Form 4, 13F) where the evidence lives.
Q3 2026 Biotech Catalyst Calendar: PDUFA Dates and Readouts to Watch
The confirmed PDUFA dates and clinical readouts driving biotech stocks through the rest of Q3 2026 — five FDA decisions and a slate of Phase 2/3 topline data, each traceable to the trial record.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
Biotech rNPV Valuation: Formula, Worked Example and Assumption Checklist
Understand risk-adjusted NPV without confusing enterprise and equity value. Work through a hypothetical biotech example and check the evidence behind each assumption.
Surrogate Endpoints in Oncology: ORR, PFS, and Overall Survival
How oncology surrogate endpoints like ORR and PFS relate to overall survival, why they enable faster approvals, and the risks investors must weigh when survival data lag.
Understanding Mechanism of Action (MoA) in Biotech Investing
Why a drug's mechanism of action drives differentiation, competitive risk, and side effects, and how investors can use MoA to evaluate a pipeline without a science degree.
13F Filings: Tracking Institutional Money in Biotech
How to use quarterly 13F filings to see which funds are building or exiting biotech positions, what the data can and can't tell you, and the timing pitfalls to avoid.
Bispecific Antibodies Explained: Two Targets, One Molecule
How bispecific antibodies engage two targets at once, why T-cell engagers are reshaping oncology, and what investors should weigh versus ADCs and CAR-T.
ClinicalTrials.gov Trial Start Dates: Recruiting vs Actual Enrollment
Check whether a biotech trial has actually started: distinguish estimated dates, recruiting status, enrollment targets and primary completion, with dated NVG-291 and NAI examples.
Clinical Trial Enrollment: Does the Actual Count Support the Design?
Check estimated versus actual enrollment, the protocol's sample-size assumptions, analysis populations, and follow-up before treating a trial as ready to read out.
How to Screen for Undervalued Biotech Stocks
A practical framework for screening biotech — combining cash, catalysts, pipeline quality, and valuation — and how natural-language screening speeds the hunt.
mRNA Platforms Beyond Vaccines: The Investment Thesis
How mRNA technology works, why it's a platform rather than a single product, and the opportunities and challenges as developers push beyond vaccines into therapeutics.
Royalty and Milestone Deals: How Biotech Partnerships Create Value
How upfront payments, milestones, and royalties work in biotech licensing and partnership deals, and why they're a key non-dilutive financing and validation signal.
AAV Gene Therapy Trials: Eligibility, Dose and Durability
Compare AAV gene therapy evidence using patient eligibility, dose units, endpoints and observed follow-up. Build a trial worksheet before making valuation assumptions.
Patent Cliffs and Loss of Exclusivity in Biotech
How patent expiry and loss of exclusivity reshape pharma revenue, the difference between small-molecule generics and biosimilars, and how investors model the cliff.
Going Concern Warnings: The Biotech Red Flag in the Footnotes
What a going concern qualification means, why it's common in clinical-stage biotech, and how investors should weigh it against the pipeline and catalyst timeline.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
Building a Biotech Catalyst Calendar That Actually Works
How to build and maintain a catalyst calendar for biotech investing — which events to track, where the dates come from, and why a stale calendar is worse than none.
CAR-T Cell Therapy Explained for Investors
How CAR-T re-engineers a patient's immune cells to fight cancer, the manufacturing and safety challenges that shape its economics, and what investors should watch.
How to Read a Biotech 10-K: The Sections That Actually Matter
A focused guide to the annual 10-K for biotech investors — risk factors, liquidity, pipeline disclosures, and the footnotes where the real story often hides.
Statistical Significance and P-Values in Clinical Trials
What a p-value actually means, why p<0.05 is the bar, the difference between statistical and clinical significance, and how to avoid being fooled by a 'trend.'
Binary Events and Biotech Volatility: Managing the Big Swings
Why biotech stocks move violently on single catalysts, how to think about binary risk and position sizing, and the behavioral traps around make-or-break events.
Biotech Dilution and ATM Offerings: The Financing Treadmill
Why clinical-stage biotechs dilute constantly, how at-the-market (ATM) offerings work, and how to assess financing risk before it hits the share count.
Primary vs Secondary Endpoints: Audit a Trial Readout
Check a clinical trial readout against its endpoint definitions, testing hierarchy and analysis population. Separate confirmatory results from exploratory signals.
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
What Is an Antibody-Drug Conjugate (ADC)? An Investor's Primer
How antibody-drug conjugates deliver potent payloads to cancer cells, the three components that define them, and why ADCs have become one of oncology's hottest modalities.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
How to Screen Biotech Stocks with Natural Language: Beyond Traditional Stock Screeners
Discover how natural language screening lets biotech investors compile plain-English criteria into executable company screens instead of rebuilding spreadsheet filters.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Biotech Earnings Reports: Key Metrics Beyond Revenue That Drive Stock Prices
Learn what to look for in biotech quarterly earnings reports, from cash burn and pipeline updates to guidance changes and hidden signals that move stock prices.
FDA Priority Review: Timing vs. Approval Probability
Check the correct FDA review clock, separate a PDUFA action goal from approval odds, and audit the timing and probability assumptions in a biotech valuation.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Biotech Insider Trading Signals: What Form 4 Filings Reveal About Stock Direction
Learn how to interpret SEC Form 4 insider trading filings for biotech companies, identify meaningful insider buying patterns, and avoid common misinterpretations.
Patent Expiry in Biotech: How Loss of Exclusivity Impacts Stock Valuations
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
Biotech Cash Runway: Funding Before the Next Milestone
Build a dated cash-runway worksheet from filings. Separate usable cash, operating burn, financing and milestone assumptions before judging a biotech's funding gap.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
FDA Complete Response Letters: How to Verify a Resubmission Timeline
Separate CRL remediation from the FDA review clock. Check the original letter, resubmission receipt, Class 1 or Class 2 designation, and confirmed goal date.
What Is PDUFA? A Complete Guide for Biotech Investors
Understand PDUFA dates, how the FDA review process works, and why PDUFA action dates are the most important catalysts in biotech investing.
How to Read FDA Advisory Committee (AdCom) Meeting Results
Learn how FDA Advisory Committee meetings work, how to interpret voting results, and what AdCom outcomes mean for biotech stock prices.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
SEC Filing Analysis for Biotech Companies: Key Filings Every Investor Should Read
Learn which SEC filings matter most for biotech companies, what to look for in 10-K, 10-Q, 8-K, and S-1 filings, and how to extract actionable insights.
How AI Is Transforming Biotech Investment Research
Explore how AI changes biotech due diligence when a natural-language thesis becomes an executable, evidence-gated research protocol.
Drug Modalities & Science
The science behind modern therapeutics — antibody-drug conjugates, CAR-T cell therapy, and how a drug’s mechanism of action drives differentiation and risk.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
Surrogate Endpoints in Oncology: ORR, PFS, and Overall Survival
How oncology surrogate endpoints like ORR and PFS relate to overall survival, why they enable faster approvals, and the risks investors must weigh when survival data lag.
Understanding Mechanism of Action (MoA) in Biotech Investing
Why a drug's mechanism of action drives differentiation, competitive risk, and side effects, and how investors can use MoA to evaluate a pipeline without a science degree.
Bispecific Antibodies Explained: Two Targets, One Molecule
How bispecific antibodies engage two targets at once, why T-cell engagers are reshaping oncology, and what investors should weigh versus ADCs and CAR-T.
FDA Refuse to File (RTF): The Rejection Before the Review
A Refuse to File is the FDA declining to even review an application. Learn what triggers an RTF, how it differs from a Complete Response Letter, and what it signals.
Clinical Trial Enrollment: Does the Actual Count Support the Design?
Check estimated versus actual enrollment, the protocol's sample-size assumptions, analysis populations, and follow-up before treating a trial as ready to read out.
mRNA Platforms Beyond Vaccines: The Investment Thesis
How mRNA technology works, why it's a platform rather than a single product, and the opportunities and challenges as developers push beyond vaccines into therapeutics.
What Is FDA Rolling Review? How It Compresses Drug Timelines
Rolling review lets sponsors submit application sections as they're completed instead of all at once. Here's how it works, who qualifies, and what it means for catalyst timing.
AAV Gene Therapy Trials: Eligibility, Dose and Durability
Compare AAV gene therapy evidence using patient eligibility, dose units, endpoints and observed follow-up. Build a trial worksheet before making valuation assumptions.
Open-Label vs Double-Blind Trials: An Investor's Evidence Checklist
Assess an open-label readout using its comparator, randomization, masked outcome assessment and missing data. See which safeguards support a comparison and what remains unknown.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
CAR-T Cell Therapy Explained for Investors
How CAR-T re-engineers a patient's immune cells to fight cancer, the manufacturing and safety challenges that shape its economics, and what investors should watch.
Statistical Significance and P-Values in Clinical Trials
What a p-value actually means, why p<0.05 is the bar, the difference between statistical and clinical significance, and how to avoid being fooled by a 'trend.'
Primary vs Secondary Endpoints: Audit a Trial Readout
Check a clinical trial readout against its endpoint definitions, testing hierarchy and analysis population. Separate confirmatory results from exploratory signals.
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
What Is an Antibody-Drug Conjugate (ADC)? An Investor's Primer
How antibody-drug conjugates deliver potent payloads to cancer cells, the three components that define them, and why ADCs have become one of oncology's hottest modalities.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Patent Expiry in Biotech: How Loss of Exclusivity Impacts Stock Valuations
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Investing Strategy & Catalysts
Putting it together — building a catalyst calendar, navigating binary events, screening for value, and compiling reusable research protocols for biotech due diligence.
Q3 2026 Biotech Catalyst Calendar: PDUFA Dates and Readouts to Watch
The confirmed PDUFA dates and clinical readouts driving biotech stocks through the rest of Q3 2026 — five FDA decisions and a slate of Phase 2/3 topline data, each traceable to the trial record.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
Biotech rNPV Valuation: Formula, Worked Example and Assumption Checklist
Understand risk-adjusted NPV without confusing enterprise and equity value. Work through a hypothetical biotech example and check the evidence behind each assumption.
Surrogate Endpoints in Oncology: ORR, PFS, and Overall Survival
How oncology surrogate endpoints like ORR and PFS relate to overall survival, why they enable faster approvals, and the risks investors must weigh when survival data lag.
Understanding Mechanism of Action (MoA) in Biotech Investing
Why a drug's mechanism of action drives differentiation, competitive risk, and side effects, and how investors can use MoA to evaluate a pipeline without a science degree.
13F Filings: Tracking Institutional Money in Biotech
How to use quarterly 13F filings to see which funds are building or exiting biotech positions, what the data can and can't tell you, and the timing pitfalls to avoid.
Bispecific Antibodies Explained: Two Targets, One Molecule
How bispecific antibodies engage two targets at once, why T-cell engagers are reshaping oncology, and what investors should weigh versus ADCs and CAR-T.
ClinicalTrials.gov Trial Start Dates: Recruiting vs Actual Enrollment
Check whether a biotech trial has actually started: distinguish estimated dates, recruiting status, enrollment targets and primary completion, with dated NVG-291 and NAI examples.
Clinical Trial Enrollment: Does the Actual Count Support the Design?
Check estimated versus actual enrollment, the protocol's sample-size assumptions, analysis populations, and follow-up before treating a trial as ready to read out.
How to Screen for Undervalued Biotech Stocks
A practical framework for screening biotech — combining cash, catalysts, pipeline quality, and valuation — and how natural-language screening speeds the hunt.
mRNA Platforms Beyond Vaccines: The Investment Thesis
How mRNA technology works, why it's a platform rather than a single product, and the opportunities and challenges as developers push beyond vaccines into therapeutics.
Royalty and Milestone Deals: How Biotech Partnerships Create Value
How upfront payments, milestones, and royalties work in biotech licensing and partnership deals, and why they're a key non-dilutive financing and validation signal.
What Is a PDUFA Date Extension? Why the FDA Pushes Back Decisions
PDUFA extensions delay an FDA decision by up to three months. Learn why they happen, whether they're bullish or bearish, and how to interpret them as an investor.
AAV Gene Therapy Trials: Eligibility, Dose and Durability
Compare AAV gene therapy evidence using patient eligibility, dose units, endpoints and observed follow-up. Build a trial worksheet before making valuation assumptions.
Patent Cliffs and Loss of Exclusivity in Biotech
How patent expiry and loss of exclusivity reshape pharma revenue, the difference between small-molecule generics and biosimilars, and how investors model the cliff.
Going Concern Warnings: The Biotech Red Flag in the Footnotes
What a going concern qualification means, why it's common in clinical-stage biotech, and how investors should weigh it against the pipeline and catalyst timeline.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
Building a Biotech Catalyst Calendar That Actually Works
How to build and maintain a catalyst calendar for biotech investing — which events to track, where the dates come from, and why a stale calendar is worse than none.
CAR-T Cell Therapy Explained for Investors
How CAR-T re-engineers a patient's immune cells to fight cancer, the manufacturing and safety challenges that shape its economics, and what investors should watch.
How to Read a Biotech 10-K: The Sections That Actually Matter
A focused guide to the annual 10-K for biotech investors — risk factors, liquidity, pipeline disclosures, and the footnotes where the real story often hides.
Statistical Significance and P-Values in Clinical Trials
What a p-value actually means, why p<0.05 is the bar, the difference between statistical and clinical significance, and how to avoid being fooled by a 'trend.'
Binary Events and Biotech Volatility: Managing the Big Swings
Why biotech stocks move violently on single catalysts, how to think about binary risk and position sizing, and the behavioral traps around make-or-break events.
Biotech Dilution and ATM Offerings: The Financing Treadmill
Why clinical-stage biotechs dilute constantly, how at-the-market (ATM) offerings work, and how to assess financing risk before it hits the share count.
Primary vs Secondary Endpoints: Audit a Trial Readout
Check a clinical trial readout against its endpoint definitions, testing hierarchy and analysis population. Separate confirmatory results from exploratory signals.
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
What Is an Antibody-Drug Conjugate (ADC)? An Investor's Primer
How antibody-drug conjugates deliver potent payloads to cancer cells, the three components that define them, and why ADCs have become one of oncology's hottest modalities.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
How to Screen Biotech Stocks with Natural Language: Beyond Traditional Stock Screeners
Discover how natural language screening lets biotech investors compile plain-English criteria into executable company screens instead of rebuilding spreadsheet filters.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Biotech Earnings Reports: Key Metrics Beyond Revenue That Drive Stock Prices
Learn what to look for in biotech quarterly earnings reports, from cash burn and pipeline updates to guidance changes and hidden signals that move stock prices.
FDA Priority Review: Timing vs. Approval Probability
Check the correct FDA review clock, separate a PDUFA action goal from approval odds, and audit the timing and probability assumptions in a biotech valuation.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Biotech Insider Trading Signals: What Form 4 Filings Reveal About Stock Direction
Learn how to interpret SEC Form 4 insider trading filings for biotech companies, identify meaningful insider buying patterns, and avoid common misinterpretations.
Patent Expiry in Biotech: How Loss of Exclusivity Impacts Stock Valuations
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
Biotech Cash Runway: Funding Before the Next Milestone
Build a dated cash-runway worksheet from filings. Separate usable cash, operating burn, financing and milestone assumptions before judging a biotech's funding gap.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
FDA Complete Response Letters: How to Verify a Resubmission Timeline
Separate CRL remediation from the FDA review clock. Check the original letter, resubmission receipt, Class 1 or Class 2 designation, and confirmed goal date.
What Is PDUFA? A Complete Guide for Biotech Investors
Understand PDUFA dates, how the FDA review process works, and why PDUFA action dates are the most important catalysts in biotech investing.
How to Read FDA Advisory Committee (AdCom) Meeting Results
Learn how FDA Advisory Committee meetings work, how to interpret voting results, and what AdCom outcomes mean for biotech stock prices.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
SEC Filing Analysis for Biotech Companies: Key Filings Every Investor Should Read
Learn which SEC filings matter most for biotech companies, what to look for in 10-K, 10-Q, 8-K, and S-1 filings, and how to extract actionable insights.
How AI Is Transforming Biotech Investment Research
Explore how AI changes biotech due diligence when a natural-language thesis becomes an executable, evidence-gated research protocol.
From concept to criterion
Use what you learned inside a real thesis
Choose the company, drug, or catalyst where this framework should become a rule, check, or blocker.